Singapore markets closed

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
53.24-4.06 (-7.09%)
At close: 04:00PM EDT
53.36 +0.12 (+0.23%)
After hours: 07:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close57.30
Open57.38
Bid53.11 x 400
Ask53.33 x 200
Day's range52.78 - 57.98
52-week range19.81 - 61.61
Volume1,717,694
Avg. volume874,206
Market cap3.587B
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)-2.73
Earnings date05 Aug 2024 - 09 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est78.50
  • GlobeNewswire

    Merus Announces Pricing of Upsized Public Offering of Common Shares

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purch

  • Simply Wall St.

    These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat

    The latest analyst coverage could presage a bad day for Merus N.V. ( NASDAQ:MRUS ), with the analysts making...

  • GlobeNewswire

    Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET. The webcast of the presentation will be contemporaneous